Functional Antagonism of Chemokine Receptor CCR1 Reduces Mortality in Acute Pneumovirus Infection In Vivo

AUTOR(ES)

Bonville, Cynthia A.

FONTE

American Society for Microbiology

RESUMO

We present an antiviral-immunomodulatory therapeutic strategy involving the chemokine receptor antagonist Met-RANTES, which yields significant survival in the setting of an otherwise fatal respiratory virus infection. In previous work, we demonstrated that infection with the natural rodent pathogen pneumonia virus of mice involves robust virus replication accompanied by cellular inflammation modulated by the CC chemokine macrophage inflammatory protein 1α (MIP-1α). We found that the antiviral agent ribavirin limited virus replication in vivo but had no impact on morbidity and mortality associated with this disease in the absence of immunomodulatory control. We show here that ribavirin reduces mortality, from 100% to 10 and 30%, respectively, in gene-deleted CCR1−/− mice and in wild-type mice treated with the small-molecule chemokine receptor antagonist, Met-RANTES. As MIP-1α-mediated inflammation is a common response to several distantly related respiratory virus pathogens, specific antiviral therapy in conjunction with blockade of the MIP-1α/CCR1 inflammatory cascade may ultimately prove to be a useful, generalized approach to severe respiratory virus infection and its pathological sequelae in human subjects.

Documentos Relacionados

• Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection
• Lack of chemokine receptor CCR1 enhances Th1 responses and glomerular injury during nephrotoxic nephritis
• Targeted disruption of the beta-chemokine receptor CCR1 protects against pancreatitis-associated lung injury.
• A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation
• The chemokine monocyte chemoattractant protein-1 induces functional responses through dimerization of its receptor CCR2